Company / Accounts Receivable
Theravance Biopharma, Inc. Accounts Receivable History
FY2016-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$620.0K
FY2018
5-year range
-
FY2016-FY2018
Trend
-72.5%
vs FY2017
Sector context
#109 of 113
Health Care
What the data says
Among 113 Health Care companies, Theravance Biopharma, Inc. is in the bottom 4% for accounts receivable. Declined from $646,000 to $620,000 over the past 2 years.
Based on SEC 10-K filings.
$620,000 in FY2018.
Declined from $646,000 to $620,000 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 113This company $620.0K Sector average $1.1B
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2018, accounts receivable decreased 72.5% year-over-year.
- Ranks #109 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $620.0K | -72.5% |
| FY2017 | $2.3M | +248.8% |
| FY2016 | $646.0K | +416.8% |
As of FY2018 · SEC 10-K · Updated Jun 30, 2026